Ischaemic Events and Stent Thrombosis following Planned Discontinuation of Study Treatment with Ticagrelor or Clopidogrel in the PLATO Study

Robert F. Storey; Diego Ardissino; Luigi Vignali; Richard Cairns; Richard C. Becker; Christopher P. Cannon; Kenneth W. Mahaffey; Anders Himmelmann; Hugo A. Katus; Stefan K. James; Lars Wallentin; on behalf of the PLATO Investigators

doi:10.1160/TH17-05-0355

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2018; 118(02): 427-429
DOI: 10.1160/TH17-05-0355

Letter to the Editor

Schattauer GmbH Stuttgart

Ischaemic Events and Stent Thrombosis following Planned Discontinuation of Study Treatment with Ticagrelor or Clopidogrel in the PLATO Study

Robert F. Storey

,

Diego Ardissino

,

Luigi Vignali

,

Richard Cairns

,

Richard C. Becker

,

Christopher P. Cannon

,

Kenneth W. Mahaffey

,

Anders Himmelmann

,

Hugo A. Katus

,

Stefan K. James

,

Lars Wallentin

,

on behalf of the PLATO Investigators

Abstract

Full Text

References

References
1 Steg PG, James SK, Atar D. , et al; Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology (ESC). ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33 (20) 2569-2619
2 Roffi M, Patrono C, Collet JP. , et al; Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 2016; 37 (03) 267-315
3 Mehran R, Baber U, Steg PG. , et al. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet 2013; 382 (9906): 1714-1722
4 Mauri L, Kereiakes DJ, Yeh RW. , et al; DAPT Study Investigators. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 2014; 371 (23) 2155-2166
5 Bonaca MP, Bhatt DL, Steg PG. , et al. Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54. Eur Heart J 2016; 37 (14) 1133-1142
6 Ho PM, Peterson ED, Wang L. , et al. Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome. JAMA 2008; 299 (05) 532-539
7 James S, Åkerblom A, Cannon CP. , et al. Comparison of ticagrelor, the first reversible oral P2Y₁₂ receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J 2009; 157 (04) 599-605
8 Wallentin L, Becker RC, Budaj A. , et al; PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361 (11) 1045-1057
9 Gurbel PA, Bliden KP, Butler K. , et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 2009; 120 (25) 2577-2585
10 Frelinger III AL, Barnard MR, Fox ML, Michelson AD. The Platelet Activity After Clopidogrel Termination (PACT) study. Circ Cardiovasc Interv 2010; 3 (05) 442-449
11 Spertus JA, Kettelkamp R, Vance C. , et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation 2006; 113 (24) 2803-2809

Supplementary Material

Supplementary Materials